By Business/Source
Currency:CNY
2025/H1
Stock NameRevenueRatio
神经介入业务191.77M54.27%
经导管瓣膜治疗业务161.61M45.73%
By Product
Currency:CNY
2025/H1
Stock NameRevenueRatio
神经介入业务191.77M54.27%
经导管瓣膜治疗业务161.61M45.73%
By Country/Region
Currency:CNY
2025/H1
Stock NameRevenueRatio
China353.38M100.00%